Improving survival and reducing treatment damage in Hodgkin lymphoma.

Impact: Health and wellbeing


Our research has led to fundamental treatment changes in Hodgkin lymphoma (HL):
• Individualising treatment, leading to fewer treatment-related second cancers and less heart disease for early stage HL patients, and less lung damage in advanced HL.
• Changing clinical guidelines on radiotherapy treatment, reducing dose and field size, decreasing patient risk.
• Introduction of Brentuximab Vedotin in Europe and US for advanced HL, the first new treatment option and change to clinical practice in over 40 years.
• Creation of national Breast Screening after Radiotherapy (BARD) dataset, which identifies women at risk of radiotherapy-induced breast cancer following HL treatment, and its introduction into Public Health England policy.
Impact date1 Aug 201331 Dec 2020
Category of impactHealth and wellbeing
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Cancer
  • Manchester Cancer Research Centre